forum

DRREDDY Share Price Discussion

Dr. Reddy's Laboratories Ltd.
Sector: Pharmaceuticals and health care
... Read more
DRREDDY Share Price *
2,682.1 +30.2 (1.14%)
* (quote may be delayed)

DRREDDY Discussion Forum

Equity FnO & Crude Hub in DRREDDY
DRREDDY CAN BE BOUGHT NEAR 2675-2680 WITH SL AT...

2693 NOW
Like
reply
Reply
share
Share

DRREDDY CAN BE BOUGHT NEAR 2675-2680 WITH SL AT 2660 - TARGET 2700 & ABOVE
Like
reply
Reply
share
Share

Buy dr reddy 2700 ce @61.50 tgt 69 sl 60
64🔥🔥
Like
reply
Reply
share
Share
Dr. Reddy’s Q2 PAT may dip 10% YoY to Rs. 455.9 cr: Emkay
Net Sales are expected to increase by 9.7 percent Y-o-Y (up 8.4 percent Q-o-Q) to Rs. 4,167.1 crore, according to Emkay.
Moneycontrol
Like
reply
Reply
share
Share

Axis Direct Recommendation on DRREDDY
Date: 11-Oct-19 Broker: Axis Direct Price @ Call: 2637.35 Target: 2900 Recommendation: BUY
Like
reply
Reply
share
Share

DRREDDY - chart - 393753
DRREDDY looking bullish
Like
reply
Reply
share
Share

**RISKY OPTION CALL**
================
**STOCK:** DR REDDY 2600 PE @ 59.85
**STOPLOSS :** YOURS
**TARGET: ** 65.00
**LOT SIZE:** 250
Like
reply
Reply
share
Share
Indian pharma market sees growth of 11.5% in Q2FY20
The July-October period saw outbreaks of infectious diseases in many parts of the country, aiding the growth of anti-infective segment to 14 percent YoY in the second quarter, beating overall IPM growth.
Moneycontrol
Like
reply
Reply
share
Share
Indian pharma market registers growth of 11.5% in Q2FY20
The July-October period saw outbreaks of infectious diseases in many parts of the country, aiding the growth of anti-infective segment to 14 percent YoY in the second quarter, beating overall IPM growth.
Moneycontrol
Like
reply
Reply
share
Share
D-Street Buzz: Nifty Pharma falls 2%; Glenmark, Auro Pharma, Piramal Enterprises, Lupin touch 52-week lows
Shares of Glenmark Pharmaceuticals fell after the US Food & Drug Administration issued a warning letter to the company's Baddi facility.
Moneycontrol
Like
reply
Reply
share
Share

07-10-19
DRREDDY OCT PE 2600 (Intraday)
only above 78.20
Like
reply
Reply (6)
share
Share
Latest replies
Sameer  @tradingfab
Oct 7 3:28 PM

High 80.60 ********
Sameer  @tradingfab
Oct 7 3:28 PM

High 81 **********
Sameer  @tradingfab
Oct 7 3:29 PM

High 82 ******
Sameer  @tradingfab
Oct 7 3:31 PM

High 84.95 *******
Sameer  @tradingfab
Oct 7 3:36 PM

High 85.60 *******
Stocks in the news: Glenmark Pharma, Ashok Leyland, Lupin, VST Tillers, BEML, SPARC
Apar Industries | Ashok Leyland | Prakash Industries | Eveready Industries and JSW Steel are stocks, which are in news today.
Moneycontrol
Like
reply
Reply
share
Share
USFDA issues Establishment Inspection Report for Dr Reddy's Bollaram plant
The receipt of EIR indicated closure of the audit of the Bollaram facility
Moneycontrol
Like
reply
Reply
share
Share

DRREDDY - chart - 387388
Dr Reddy fails to surpass the confluence level of the fibs. Weekly RSI indicates stock could witness selling pressure. Intermediate supports placed at 2520, break of which will open the way for lower moves until 2400-2350.
Like
reply
Reply
share
Share
santosh gupta in DRREDDY
FOM: SELL DRREDDY BELOW 2680

FOM: ONCE EXIT SHORT IN DRREDDY AT 2667. BOOK PROFIT RS. 3,250.00. NSE
Like
reply
Reply
share
Share

DR REDDY FUT BUY @ 2658-60
SL 2647
Target 2700++
Like
reply
Reply
share
Share

FOM: SELL DRREDDY BELOW 2680
Like
reply
Reply
share
Share

Stock Update: SELL DRREDDY AT 2660 WITH SL 2705
TGT OPEN
Like
reply
Reply
share
Share
Ranitidine controversy: Which Indian pharma companies stand to lose?
Moneycontrol
Like
reply
Reply
share
Share

**OPTION CALL**
================
**STOCK:** DRREDDY 2750 PE @ 71.00
**STOPLOSS :** YOURS
**TARGET: ** 79.00
**LOT SIZE:** 250
Like
reply
Reply (1)
share
Share
Latest replies
INTRADAY Options @teamIOFno
Sep 27 8:55 PM

95.00
Dr. Reddy’s Is First Indian Pharma Firm Accepted Under China’s New Drug-Buying Plan
Dr. Reddy’s Laboratories has bagged the rights to supply Olanzapine, a key drug to treat schizophrenia, in China.
BloombergQuint
Like
reply
Reply
share
Share

Nomura On Dr Reddy’s
Maintain Buy, TP Rs 3284
Big Opportunity For Co Is Clopidogrel
Believe Co May Participate In Tender Bids In FY20
Co Conducting Biostudies To Qualify For Tenders
Clopidogrel Market Is More Than $1 Bn In Size
Like
reply
Reply
share
Share
GSK suspends Ranitidine distribution in India, regulators seek drug testing data from pharma cos
Sources within pharma industry told Moneycontrol that Dr Reddy’s and Saraca Laboratories are two big suppliers of the Ranitidine active pharmaceutical ingredient (API) globally, from which most other companies source the API to formulate the drug.
Moneycontrol
Like
reply
Reply
share
Share

Karvy Stock Broking Recommendation on DRREDDY
Date: 25-Sep-19 Broker: Karvy Stock Broking Price @ Call: 2784.6 Target: 3259 Recommendation: BUY
Like
reply
Reply
share
Share
Ankush Deshpande in DRREDDY
Sell dr reddy 2765 sl 2775 Target 2753 2743

2760
Like
reply
Reply
share
Share

Sell dr reddy 2765 sl 2775
Target 2753 2743
Like
reply
Reply
share
Share

BUY DRREDDY
Like
reply
Reply
share
Share

24-09-19
DRREDDY SEP CE 2800 (Intraday)
only above @ 29
Like
reply
Reply (6)
share
Share
Latest replies
Sameer  @tradingfab
Sep 24 3:19 PM

High 34 *****
Sameer  @tradingfab
Sep 24 3:19 PM

High 35 *****
Sameer  @tradingfab
Sep 24 3:26 PM

High 37 *******
Sameer  @tradingfab
Sep 24 3:27 PM

High 40.50 ******
Sameer  @tradingfab
Sep 24 3:30 PM

High 63 *******
Market registers yet another thumping close; 42 stocks in BSE500 gain 10-19% in 2 days
On the sectoral front, except IT and pharma, all other indices are ended higher led by the FMCG, bank, infra, auto, metal and energy.
Moneycontrol
Like
reply
Reply
share
Share

"RISKY JACKPOT"
DRREDDY BUY ABOVE 2718
SL 2716
TARGET "OPEN"
Like
reply
Reply (2)
share
Share
Latest replies

NEW HIGH 2745
(-500/- RISK PER LOT)😍
RISK 1: 13.50 TIMES PROFIT❤️
6,750/- PROFIT TILL NOW👍

NEW HIGH 2778++
(-500/- RISK PER LOT)😍
RISK 1: 30 TIMES PROFIT❤️
15,000/- PROFIT👍

DRREDDY - chart - 370063
Drreddy
Like
reply
Reply
share
Share
santosh gupta in DRREDDY
OPTION CALL: BUY DRREDDY SEP 2800 CE ABV 38 SL...

OPTION CALL: ONCE EXIT LONG IN DRREDDY AT 31. BOOK LOSS RS. 1,750.00. NSE
Like
reply
Reply
share
Share

OPTION CALL: BUY DRREDDY SEP 2800 CE ABV 38 SL BELOW 28.5 TGT 55.1-60.8. CMP: 38
Like
reply
Reply
share
Share

🌹Sell drredy 2732 target 2718 2698 2690 sl 2746
Like
reply
Reply (1)
share
Share
Latest replies
rohit raval @rohitraval
Sep 20 3:58 PM

Drreddy 2720 runingggggg🧚‍♀🧚‍♀🧚‍♀🧚‍♀🧚‍♀🧚‍♀🧚‍♀🧚‍♀🧚‍♀🧚‍♀🧚‍♀

🌹Sell drredy 2732 target 2718 2698 2690 sl 2746
Like
reply
Reply
share
Share

DRREDDY - chart - 365230

Like
reply
Reply
share
Share
60% of Nifty and 70% of Nifty500 stocks record ‘Death Cross’ on daily charts; a major selloff imminent?
The Nifty50 might have turned negative for the year 2019, but almost 60% of the companies in the index are in a bear grip as they have registered formation of a ‘Death Cross’.
Moneycontrol
Like
reply
Reply
share
Share

"RISKY JACKPOT"
DRREDDY BUY ABOVE 2735
SL 2729
TARGET "OPEN"
Like
reply
Reply (3)
share
Share
Latest replies

NEW HIGH 2740++
(-1500/- RISK PER LOT)😍
RISK 1: 1 TIMES PROFIT❤️
1,400/- PROFIT TILL NOW👍

NEW HIGH 2747++
(-1500/- RISK PER LOT)😍
RISK 1: 2 TIMES PROFIT❤️
3,000/- PROFIT TILL NOW👍

NEW HIGH 2753++
(-1500/- RISK PER LOT)😍
RISK 1: 3 TIMES PROFIT❤️
4,500/- PROFIT TILL NOW👍

CS On Dr Reddy’s
O-P, TP Rs 3055
Launch Momentum Stays Strong In The US
Estimate FY19-22 EBITDA CAGR Of 22% & RoCE To Double To 22%
Stock Has Multiple Option Values From China Injectable Opportunity
Like
reply
Reply
share
Share
Market Headstart: Nifty likely to open flat; Britannia, GNFC top buying ideas
Trends on SGX Nifty indicate a flat to positive opening for the broader index in India, with a 10 points gain or 0.09 percent. Nifty futures were trading around 11,001.50-level on the Singaporean Exchange.
Moneycontrol
Like
reply
Reply
share
Share
Dr Reddy's launches heartburn capsules in US market
The company has launched Lansoprazole delayed-release capsules USP in the strength of 15 mg in the US market, as approved by the United States Food and Drug Administration (USFDA), Dr Reddy's said in a BSE filing.
Moneycontrol
Like
reply
Reply
share
Share

Performance for the WEEK*
Trade posted on 8.9.19
Drreddy ce 2750* cmp 60.95 buy upto 32.00 stop 18.00 target 128.00+
Entry 53 to 81
*profit 7,000*
1
reply
Reply (6)
share
Share
Latest replies

But it made high of 81 on friday opening
DOMINIC @dominic
Sep 14 4:42 PM

I have missed that time.
Will see next week sir.
Thanks for the reply
Dev @dev-BkQkcKXer
Sep 17 6:32 PM

Is there any chance to get 2800+?
Dev @dev-BkQkcKXer
Sep 17 6:33 PM

I have 2800CE

DRREDDY - chart - 356882
What a top class alert on chart we get with this Metastock Compatible Price Plotting Indicator and Setup
Like
reply
Reply (1)
share
Share
Latest replies
Dev @dev-BkQkcKXer
Sep 14 8:41 PM

What would be the result? Up or down?

Buy DrReddy future abv 2735 for 2738 2741 2745
Like
reply
Reply (2)
share
Share
Latest replies

Second trgt achieved 👍👍
High made 2742

All trgt achieved 👍👍👍
High made 2747

drredy 2765 to 2700 + 65000
chapo india chapo
Like
reply
Reply
share
Share

💎💎💎
YOUR FREE GIFT EQUITY CASH CALL FOR THE DAY!!
BUY DRREDDY AT THE VERY BEGINING
STRICT STOP LOSS - 2740
TARGET - 2792/2795/2799
PLEASE AVOID IF IT OPENS GAP UP MORE THAN 1.5%
Disclaimer: All my Views/Suggestions/Calls are for Education Purpose Only. Please consult with your...
Read more...
Like
reply
Reply
share
Share
Market Headstart: Nifty seen opening higher; HDFC Bank, Castrol top buys
Trends on SGX Nifty indicate a flat to positive opening for the broader index in India, with a 10 points gain or 0.09 percent. Nifty futures were trading around 11,001.50-level on the Singaporean Exchange.
Moneycontrol
Like
reply
Reply
share
Share
Stocks in the news: Dr Reddy's Labs, PNB, SBI, PVR, Oriental Bank, DHFL, L&T Finance
Dr Reddy's Labs | PNB | State Bank of India | PVR | Oriental Bank of Commerce | DHFL | L&T Finance Holdings are the stocks which are in news today.
Moneycontrol
Like
reply
Reply
share
Share

drreddy +15000
derisk n hold
Like
reply
Reply
share
Share
Q. What would be the target for next few days? Will it cross 2800?
Like
reply
Reply (2)
share
Share
Latest replies
Tipu Pahan @tipupahan
Sep 13 5:42 PM

its now in bear's grip.. will get testing around 2640 level in coming days

Reversal seen in these script ,not able to touch 2800,heavy resistance at 2800
  • DRREDDY - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization46,050.89
    Enterprise Value46,829.69
    Price to Earnings61.08
    Price to Book Value3.63
    Return on Capital Employed0.05
    Return on Equity0.05
    Face Value5
    Dividend Yield0.01
  • DRREDDY Share Price - Technicals

    keyboard_arrow_down
    DRREDDY - 52 Week High₹2,964
    DRREDDY - 52 Week Low₹1,872.95
  • DRREDDY - Brokerage Reports

    keyboard_arrow_down
    DateBrokerageCallTarget
    11-Oct-19Axis DirectBuy2,900
    25-Sep-19Karvy Stock BrokingBuy3,259
    2-Aug-19Nirmal BangBuy3,281
    31-Jul-19HDFC SecuritiesBuy3,360
    30-Jul-19Prabhudas LilladherAccumulate2,997
    View all DRREDDY - Share Targets - Broker Reports
  • DRREDDY Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Oct 1526622696.92654.552684.65
    Oct 1426522682.626212651.9
    Oct 112645265926072651.4
    Oct 102626.152666.92612.052633.5
    Oct 92624.7526762600.32663.4
  • DRREDDY Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹2,709.83
    30 Day Moving Average₹2,694.95
    50 Day Moving Average₹2,633.07
    100 Day Moving Average₹2,625.09
    200 Day Moving Average₹2,666.77
  • DRREDDY - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue9,3599,719.8-0.04
    Operating Profit1,3301,745.6-0.24
    Profit Before Tax6971,544.5-0.55
    Net Income5661,384.1-0.59
  • DRREDDY - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-19Mar-18 % Change
    Shareholder's Funds12,68411,8070.07
    Total Liabilities3,5645,545-0.36
    Total Assets16,24817,353-0.06
  • DRREDDY - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity1,5381,015.90.51
    Cash from Investing Activity-1,1801,430.5-1.82
    Cash from Financing Activity-304-2,581.8-0.88
    Net Cash Flow54-135.4-1.4
  • DRREDDY - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.030.08
    Return on Equity0.050.12
    Return on Capital Employed0.050.11
  • DRREDDY - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue-0.07
    3 Year CAGR Growth in Operating Profit-0.44
    3 Year CAGR Growth in EBIDTA-0.41
    3 Year CAGR Growth in Net Income-0.66
    3 Yr CAGR Growth - Diluted EPS-0.65
  • DRREDDY - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue0.12
    5 Year CAGR Growth in Operating Profit-0.33
    5 Year CAGR Growth in EBIDTA-0.28
    5 Year CAGR Growth in Net Income-0.55
    3 Yr CAGR Growth - Diluted EPS-0.54
  • DRREDDY Share Price - Recent News

    keyboard_arrow_down
    NewsBot
    Yesterday 9:33 PM
    Dr. Reddy’s Q2 PAT may dip 10% YoY to Rs. 455.9 cr: Emkay
    Moneycontrol
    NewsBot
    Oct 10 1:38 AM
    Indian pharma market sees growth of 11.5% in Q2FY20
    Moneycontrol
    NewsBot
    Oct 9 11:08 PM
    Indian pharma market registers growth of 11.5% in Q2FY20
    Moneycontrol
    NewsBot
    Oct 7 5:28 PM
    D-Street Buzz: Nifty Pharma falls 2%; Glenmark, Auro Pharma, Piramal Enterprises, Lupin touch 52-week lows
    Moneycontrol
    NewsBot
    Oct 7 1:13 PM
    Stocks in the news: Glenmark Pharma, Ashok Leyland, Lupin, VST Tillers, BEML, SPARC
    Moneycontrol
    NewsBot
    Oct 6 5:38 PM
    USFDA issues Establishment Inspection Report for Dr Reddy's Bollaram plant
    Moneycontrol
    NewsBot
    Sep 30 7:53 PM
    Ranitidine controversy: Which Indian pharma companies stand to lose?
    Moneycontrol
    NewsBot
    Sep 26 12:28 AM
    GSK suspends Ranitidine distribution in India, regulators seek drug testing data from pharma cos
    Moneycontrol
    NewsBot
    Sep 23 10:33 PM
    Market registers yet another thumping close; 42 stocks in BSE500 gain 10-19% in 2 days
    Moneycontrol
    NewsBot
    Sep 18 3:48 PM
    60% of Nifty and 70% of Nifty500 stocks record ‘Death Cross’ on daily charts; a major selloff imminent?
    Moneycontrol
  • DRREDDY - Related Communities

    keyboard_arrow_down
    IRCTC Sector: Miscellaneous
    Share and discuss algorithms, strateg...
    Place for new investors to ask questi...
    Help fellow traders de-stress by shar...
    Share and discuss strategies for tax ...
    Want to know more about an upcoming I...
    MCX:MENTHAOIL
    MCX:CPO
    Purpose: Pool and discuss ideas & sug...
    Sector: Index
  • DRREDDY - More Information

    keyboard_arrow_down

    Dr Reddy's Laboratories Ltd:
    Dr Reddy's Laboratories Limited has been acquiring a worldwide recognition in the pharmaceutical market for the last three decades. The company is running its operation through three core segments viz. Pharmaceutical Services and Active Ingredients (PSAI), Global Generics and Proprietary Products.
    Active pharmaceutical ingredients are manufactured and marketed by this PSAI segment. These are the essential ingredients for finished pharmaceutical products. In the basis of specific customer requirements, the company is providing active pharmaceutical ingredients and steroids. The Proprietary Product segment refers to the research and development procedures of the firm. Along with that, these segments deals with manufacturing and selling dermatological and neurological therapeutic issues.
    The company deals with several therapeutic issues such as respiratory, cardiovascular, respiratory, anti-diabetic, urology, gastrointestinal, nephrology, oncology and stomatology. The company has strong business-relation with Curis Inc. regarding the research, development and marketing of small molecules for precision oncology and precision oncology. Having its head office at Hyderabad in India, Dr Reddy's Laboratories Limited was founded in 1984.
    About Company Information:
    Soon after its establishment with an initial investment of Rs.25 lacs, the company started the manufacturing of Active Pharmaceutical Ingredients and Intermediates in a 60-tonne manufacturing plant near Hyderabad, India. The Bombay Stock Exchange enlisted the company in 1986. USDA approval for manufacturing Ibuprofen was given to the company for the first time in the year of 1987.
    For developing and expanding the market and production of Bulk Actives, the company acquired Benzex Laboratories Pvt Ltd in 1988. Norfloxacin and Ciprofloxacin were started to be exported by the company from 1990 mostly in Europe and East, just a year before commencing formulation exports to Russia in 1991. Dr Reddy's Research Foundation was inaugurated by the company in 1993.
    In 1995, the company had gone for a joint venture in Russia. Company's first ANDA was filled with United States Food and Drug Administration for manufacturing Ranitidine in 1997. India-based pharmaceutical company American Remedies Ltd was acquired by the firm in 1999.
    The company turned to be the third-largest pharmaceutical organization in India in 2000 when a merger took place between the company and Cheminor Drugs Ltd. Fluoxetine capsules were introduced by the company in 2001.
    The company commenced their debut acquisition in abroad when it acquired Meridian Healthcare and BMS Laboratories Limited at the UK in 2002. Ibuprofen was launched as the first generic under Dr Reddy's label at US market in 2003. Roche's API manufacturing business at Mexico was acquired by the company in 2005 just a year back of buying Germany's fourth-largest generic company Betapharm against an amount of Rs.480 million in 2006. Plant's first biosimilar MAb, for treating Non-Hodgkins Lymphoma was introduced by Dr Reddy's Laboratories Limited in 2007.
    A cent per cent subsidiary of the company with a 'Special Economic Zone' facility namely, Dr Reddys Pharma SEZ Ltd was established during 2009-10. At the same period, an amalgamation with Perlecan Pharma Pvt Ltd took place. The oral penicillin manufacturing plant of Glaxo Smith Kline at Tennessee in the USA was acquired by the company during 2010-11.
    US Federal Trade Commission issued an order of consent on November 2014, allowing the acquisition of Novartis Consumer Health Inc.'s Habitrol brand by Dr Reddy's Laboratories Limited which was finally announced officially by Dr Reddy's Laboratories in December 2014.
    A warning letter was issued from US Food and Drug Administration accusing Dr Reddys Laboratories Limited regarding the API manufacturing plants of the firm at Miryalaguda, Telangana and Andhra's Srikakulam along with the manufacturing facility of Oncology Formulation at Vishakhapatnam, Andhra Pradesh on November 2015. The company started to intervene in the market of Colombia with premium quality cancer medicines at affordable prices in October of 2016.
    The manufacturing, research, future development and commercialization of DFD-06, a topical steroid with enormous potential, had been out-licensed to Encore Dermatology Inc. by Promius Pharma, LLC, a cent per cent owned subsidiary of Dr Reddys Laboratories Ltd in the August of 2017.
    How Dr Reddy's Laboratories Ltd, is categorised as a Pharmaceuticals and Healthcare Sector, and Pharmaceutical Industry :
    The Pharmaceutical Industry includes companies that derive their business by researching, discovering, developing, manufacturing, and marketing and distributing pharmaceutical medicines and drugs.
    Dr Reddy's Laboratories Ltd is categorized under the Pharmaceutical and Health care sector and Pharmaceutical Industry. Healthcare sectors consist of firms involved in the medical space. It is one of the multiple sectors that comprise a range of businesses, including ones that offer medical services directly, or to those that work to develop, create and market medical equipment and medicines. It also includes the other services that provide medical insurance and other related products, and many more.
    The stocks of health care companies mostly have mixed performance. It is due to the inherent challenges to the industry each year, regulatory uncertainties, fiscal policy concerns, and more.
    Dr Reddy's Laboratories Ltd, Competitors and Sector Peers:
    Abbott India Ltd. ABBIND
    Alembic Ltd. ALELTD
    Alembic Pharmaceuticals Ltd. ALEPHA
    Alkem Laboratories Ltd. ALKLAB
    Alpa Laboratories Ltd. ALPLAB
    Ambalal Sarabhai Enterprises Ltd. AMBSAR
    AstraZeneca Pharma India Ltd. ASTZEN
    Bafna Pharmaceuticals Ltd. BAFPHA
    Bajaj Healthcare Ltd. BAJHEA
    Biocon Ltd. BIOLTD
    Cian Healthcare Ltd.
    Cipla Ltd. CIPLTD
    Concord Drugs Ltd. CONDRU
    Dishman Pharmaceuticals & Chemicals Ltd.[Merged] DISPHA
    Divi's Laboratories Ltd. DIVIL
    Dr. Reddy's Laboratories Ltd. DR
    GlaxoSmithKline Pharmaceuticals Ltd. GLAPHA
    Glenmark Pharmaceuticals Ltd. GLEPHL
    IOL Chemicals and Pharmaceuticals Ltd. IOLCHE
    Lincoln Pharmaceuticals Ltd. LINPHA
    Lupin Ltd. LUPLTD
    Madhuveer Com 18 Network Ltd. TOHPHA
    Mahavir Advanced Remedies Ltd. INDAME
    Makers Laboratories Ltd. MAKLAB
    Natco Pharma Ltd. NATPHA
    Natural Capsules Ltd. NATCAP
    Ranbaxy Laboratories Ltd. RANLAB
    Sanofi India Ltd. AVEPHA
    Sharon Bio-Medicine Ltd. SHAPHA
    Sun Pharmaceutical Industries Ltd. SUN28
    Zenith Healthcare Ltd. ZENHEA
    Zyden Gentec Ltd. ZYDGEN
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.